Articles de revue sur le cancer du sein - Dernières parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer du sein (2 février 2008):


Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer:
patient-level
meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group,
Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J,
Goldhirsch A, Gray
R, Peto R, Pritchard KI, Wood WC.
Lancet. 2008 Jan 5;371(9606):29-40.

Chemotherapy for brain metastases: breast, gynecologic and non-
melanoma skin
malignancies.
Shah GD, Abrey LE.
Cancer Treat Res. 2007;136:185-97.

Effects of study methods and biases on estimates of invasive breast
cancer
overdetection with mammography screening: a systematic review.
Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L.
Lancet Oncol. 2007 Dec;8(12):1129-38.

Management of breast cancer in elderly individuals: recommendations of
the
International Society of Geriatric Oncology.
Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-
Marty C, Hurria A,
Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M,
Giordano SH,
Muss H, Aapro M; International Society of Geriatric Oncology.
Lancet Oncol. 2007 Dec;8(12):1101-15.

Breast cancer prognostication and prediction: are we making progress?
Lønning PE.
Ann Oncol. 2007 Sep;18 Suppl 8:viii3-7.

Clinical management of adverse events in adjuvant therapy for hormone-
responsive
early breast cancer.
Monnier A.
Ann Oncol. 2007 Sep;18 Suppl 8:viii36-44.

Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant
therapy of
hormone-responsive early breast cancer.
Perez EA.
Ann Oncol. 2007 Sep;18 Suppl 8:viii26-35.

Reducing the risk of late recurrence in hormone-responsive breast
cancer.
Cufer T.
Ann Oncol. 2007 Sep;18 Suppl 8:viii18-25.

Triple negative breast carcinoma and the basal phenotype: from
expression
profiling to clinical practice.
Diaz LK, Cryns VL, Symmans WF, Sneige N.
Adv Anat Pathol. 2007 Nov;14(6):419-30.

SRC family nonreceptor tyrosine kinases as molecular targets for
cancer therapy.
Johnson FM, Gallick GE.
Anticancer Agents Med Chem. 2007 Nov;7(6):651-9.

Non-operative breast pathology: apocrine lesions.
Wells CA, El-Ayat GA.
J Clin Pathol. 2007 Dec;60(12):1313-20.

Tumor dormancy and surgery-driven interruption of dormancy in breast
cancer:
learning from failures.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M.
Nat Clin Pract Oncol. 2007 Dec;4(12):699-710.

A carrier of both MEN1 and BRCA2 mutations: case report and review of
the
literature.
Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K,
Ford
JM.
Cancer Genet Cytogenet. 2007 Dec;179(2):89-92.

Breast cancer risk associated with BRCA1 and BRCA2 in diverse
populations.
Fackenthal JD, Olopade OI.
Nat Rev Cancer. 2007 Dec;7(12):937-48.

MUC1: a target molecule for cancer therapy.
Singh R, Bandyopadhyay D.
Cancer Biol Ther. 2007 Apr;6(4):481-6.

Antiangiogenic agents in breast cancer.
Salter JT, Miller KD.
Cancer Invest. 2007 Oct;25(7):518-26.

Cancer stem cells in solid tumors.
Ailles LE, Weissman IL.
Curr Opin Biotechnol. 2007 Oct;18(5):460-6.

Early life events and conditions and breast cancer risk: from
epidemiology to
etiology.
Trichopoulos D, Adami HO, Ekbom A, Hsieh CC, Lagiou P.
Int J Cancer. 2008 Feb 1;122(3):481-5.

Ixabepilone, first in a new class of antineoplastic agents: the
natural
epothilones and their analogues.
Fornier MN.
Clin Breast Cancer. 2007 Oct;7(10):757-63.

The role of efflux pumps in drug-resistant metastatic breast cancer:
new
insights and treatment strategies.
Fojo T, Coley HM.
Clin Breast Cancer. 2007 Oct;7(10):749-56.


Protein C and its inhibitor in malignancy.
Suzuki K, Hayashi T.
Semin Thromb Hemost. 2007 Oct;33(7):667-72.

A decade of discovery of BRCA1 and BRCA2: are we turning the tide
against
hereditary breast cancers?
Sarin R.
J Cancer Res Ther. 2006 Oct-Dec;2(4):157-8.

Trastuzumab: is the new evidence revolutionary?
Munshi A, Singh P, Jalali R.
J Cancer Res Ther. 2006 Jul-Sep;2(3):144-6.

p53, BRCA1 and breast Cancer chemoresistance.
Scata KA, El-Deiry WS.
Adv Exp Med Biol. 2007;608:70-86.

Persistent use of "false" cell lines.
Lacroix M.
Int J Cancer. 2008 Jan 1;122(1):1-4.

A new breast cancer model for lymphatic metastasis.
Lizardo MM, Macdonald IC, Tuck AB, Chambers AE.
Cancer Treat Res. 2007;135:157-65.

Rexinoids and breast cancer prevention.
Howe LR.
Clin Cancer Res. 2007 Oct 15;13(20):5983-7.



(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)